Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update

Pfizer

23.66 CHF 1.10%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed its fiscal 2025 outlook.

In pre-market activity on the NYSE, Pfizer shares were trading at $26.85, up 2.5 percent.

For fiscal 2025, the company continues to expect adjusted earnings per share in a range of $2.80 to $3.00.

The Wall Street analysts on average expect the company to report earnings of $2.93 per share. Analysts' estimates typically exclude special items.

Revenues are still projected to be in the range of $61.0 billion to $64.0 billion. The Street is looking for revenues of $63 billion for the year.

Pfizer said it is maintaining full year 2025 outlook, which was provided on December 17. The company then had stated that it expects operational growth in adjusted earnings per share of 10 percent to 18 percent, year-over-year, in 2025, and operational revenue growth in a range of approximately flat to 5 percent, both from the midpoint of 2024 baseline guidance.

In fiscal 2024, the company recorded adjusted earnings per share of $3.11, on revenues of $63.6 billion.

Pfizer further said that approximately $4.5 billion of overall net cost savings from Pfizer's ongoing cost realignment program are expected to be achieved by the end of 2025.

In its fourth quarter, the company's net income was $410 million or $0.07 per share, compared to prior year's loss of $3.369 billion or $0.60 per share.

Adjusted earnings were $3.592 billion or $0.63 per share for the period, compared to $593 million or $0.10 per share a year ago.

Analysts projected earnings of $0.46 per share for the quarter.

Revenue climbed to $17.763 billion from $14.570 billion in the same period last year. The Street was looking for revenues of $17.26 billion for the quarter.

Revenues climbed 22 percent, reflecting an operational increase of 21 percent, primarily due to a one-time, non-cash Paxlovid revenue reversal of $3.5 billion recorded in fourth-quarter 2023.

Excluding contributions from Paxlovid and Comirnaty, revenues totaled $13.7 billion, an increase of 11 percent, operationally compared with the prior-year quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.